EP-1938: Evaluation of pre-treatment verification for hyperthermia treatment plans  by Marder, D. et al.
ESTRO 35 2016                                                                                                                                                    S919 
________________________________________________________________________________ 
 
 
Results: A total of 1847 pts (904 right-sided and 943 left-
sided) were treated with either 40 Gy/15 fx (912 pts) or 50 
Gy/25 fx (935 pts). 388 of the left-sided pts were treated 
with gated RT, and 440 without. No information about gating 
was available for the remaining 115 pts. Dmax(CTV) was less 
than 110% of the prescription dose in 99.4% of the plans. 
More than 2 cm3 of the CTV received 107-110% of the dose in 
1% of the hypo-fractionated plans. For the normo-
fractionated plans, this deviation was observed in 3.5% of the 
plans. For 92.3% of the hypo-fractionated plans, less than 2% 
of the CTV was covered with doses above 105%, whereas 3.9% 
and 3.5% of the plans had minor and major deviations, 
respectively. For 80.8% of the pts, the part of the CTV 
covered with at least 95% of the prescription dose was in 
compliance with the guidelines. Minor and major deviations 
were observed for 12.6% and 6.6% of the pts, respectively. By 
taking laterality into consideration, 90.8% of the right-sided 
pts were in compliance with the guidelines compared to only 
71.2% of the left-sided pts. For the left-sided pts with 
available information about gating, it was found that 87.4% 
and 59.3% of the pts treated with and without gated RT, 
respectively, were in compliance, thus indicating that 
shielding of the heart resulted in CTV under-dosage. This was 
supported by compliance to the protocol heart dose 
guidelines for 941 left-sided pts. Only one hypo-fractionated 
pt showed a major deviation in V35Gy and a minor deviation 
in V17Gy (data missing for one pt). The lung dose satisfied 
the protocol guidelines for 99.4% of the pts.  
 
Conclusion: A high degree of compliance with protocol 
guidelines was found for the DBCG HYPO trial. Only a few pts 
received CTV doses above 107% of the prescription dose. The 
CTV volume covered with less than 95% dose deviated from 
protocol guidelines for about 40% of the left-sided pts treated 
without gated RT. With gated RT this number decreased to 
about 12%, almost equal to that of right-sided pts. This 
indicates that gated RT for left-sided pts reduces the 
necessity of CTV dose compromise due to heart shielding. 
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Purpose or Objective: Stereotactic ablative radiotherapy 
(SABR) is routinely used for the treatment of early stage lung 
cancer and is increasingly used to treat other primary tumour 
sites. There are currently 6 UK studies (of which 3 are 
randomised) investigating the utility of SABR in the treatment 
of oligometastatic disease (breast, lung, prostate), lung, 
prostate, pancreas and hepatobiliary primary malignancies. 
These are supported by CRUK and currently open or in set-up 
to begin recruitment in 2016. In addition, a NHS 
Commissioning Through Evaluation (CTE) programme was 
commenced in 2015 to evaluate SABR in situations where 
clinical trials are not available. In an attempt to standardise 
protocols and the associated radiotherapy planning we sought 
to generate consensus normal tissue dose constraints 
tolerances across these UK studies. 
 
Material and Methods: Members of the various SABR studies' 
trial management groups, facilitated by the UK Radiotherapy 
Trials Quality Assurance Group (RTTQA), met to generate a 
unified table of normal tissue dose constraints. As a starting 
point, the UK SABR Consortium Guidelines, the AAPM TG-101 
report and other seminal publications were used to define a 
baseline reference. These initial constraints values were 
revised, where appropriate, by taking into consideration any 
updated or more robust data that better informed a given 
dose constraint value in the opinion of the panel.  
 
Results: Following an iterative process, agreement was 
reached on all dose constraints covering the central nervous 
system, thorax, abdomen, pelvis, skin and bone. It was 
agreed to use a point maximum dose volume of 0.5cc for the 
purposes of describing the maximum dose for all organs 
except the spinal cord. For the spinal cord 0.1cc is to be 
used. The group reached the consensus that for the purpose 
of these trials single fraction should not be used outside CNS. 
We recommended the use of 3, 5 and 8 fractions regimes. 
These dose constraints will be used for the forthcoming SABR 
studies and for the implementation of the CTE SABR 
programme for oligometastatic disease and HCC. The group 
will review the evidence annually to update the guidelines. 
 
Conclusion: A UK national agreement on SABR dose 
constraints has been successfully achieved. It is hoped that 
this unified approach will facilitate standardised 
implementation of SABR across the UK and will permit 
meaningful toxicity comparisons between SABR studies and 
further refinement of the constraints. Any further trials 
developed in the UK will adopt the consensus. 
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Purpose or Objective: The BSD-2000/3D system (BSD Medical 
Cooperation, Salt Lake City, USA) is used to treat deep 
seated tumors with hyperthermia (to temperatures of 41-
43°C) in combination with radiotherapy. Treatment planning 
for this system is done with the software SigmaHyperplan (Dr. 
Sennewald Medizintechnik GmbH, Munich, Germany). In this 
study a method and first results for pre-treatment 
verification of clinical patient treatment plans using a 3D SAR 
scanning phantom developed at the Kantonsspital Aarau are 
presented. 
 
Material and Methods: Treatment plans for individual 
patients were generated with SigmaHyperplan and applied to 
a saline phantom model. The result is a set of data for the 
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specific absorption rate (SAR) distribution. The measurement 
data is obtained with a saline phantom consisting of a tube 
with elliptical cross section. The tube is inserted into the 
BSD-2000/3D Sigma60 and a probe inside is moved in 3 spatial 
dimensions. The probe, a commercial isotropic SAR sensor, is 
scanned in 2 cm steps for a distance of 20 cm in horizontal 
and vertical directions and relative SAR values are recorded. 
Planned and measured data in the central plane of the 
applicator are compared for the location of the focus to 
assess the transferability of treatment plans to the treatment 
machine. 
 
Results: The location of the focus maximum can be 
determined from the graphs and compared to the location of 
the maximum from the simulation. For the investigated plans 
an agreement between simulation and measurement was 
found with deviations of the focal area between 0 and 2 cm. 
 
Conclusion: Good agreement for the investigated patient 
plans was found between simulation and measurement. With 
an automated measurement system higher resolutions and 2D 
or 3D comparisons would be possible. The method described 
allows the transferability of a patient treatment plan to the 
treatment machine to be verified, however it does not check 
the correct heating of the patient. 
 
EP-1939  
An optimal grid block design for spatially fractionated 
radiation therapy 
S. Gholami
1Tehran University of Medical Sciences, Medical Physics, 
Tehran, Iran Islamic Republic of 
1, H.A. Nedaie2, F. Longo3, M.R. Ay1, A. S.Meigooni4 
2Tehran University of Medical Sciences, Radiation Oncology 
Department- Cancer institute, Tehran, Iran Islamic Republic 
of 
3University of Trieste and INFN Trieste, Department of 
Physics, Trieste, Italy 
4Comprehensive Cancer Centers of Nevada, Radiation 
Oncology, Las Vegas- Nevada, USA 
 
Purpose or Objective: In the present work, we performed 
model calculations of cell survival to design a Grid block with 
optimal therapeutic ratio. The optimal Grid block was 
manufactured and dosimetric characteristics of the Grid were 
introduced. 
 
Material and Methods: The Geant4 toolkit (Version 9.6.p02) 
was used to simulate the head of the Varian2100C linear 
accelerator for a 6 MV photon beam based on the vendor 
detailed information. The dose distributions of a Grid block 
with hole-diameters of 0.5 cm, 0.75 cm, 1.0 cm, 1.25 cm, 
and 1.5 cm with constant center-to-center spacing of 1.8 cm, 
were calculated separately using the Monte Carlo simulation 
technique. A dose profile from Monte Carlo simulation, across 
a single hole of the Grid, has been utilized to calculate 
therapeutic ratio for different Grid blocks separately. The 
Hug–Kellerer (H-K) radiobiological model (Equation 1) which 
is more appropriate at doses higher than 12 Gy was utilized 
to calculate survival fraction of cell lines under a single hole 
of the Grid. The values of α/β ratios for tumor cells and 
normal cells were considered to be 10 Gy and 2.5 Gy, 
respectively. 
Equation 1: 
 
 
 
Where the Vi represents the relative cell numbers receiving 
the same dose ranging from Di and Di+1. The therapeutic 
advantage of the Grid irradiation was considered in terms of 
the normal tissue cell survival ratio (Grid/open ﬁeld ratio) for 
the same tumor cell survival. 
A Grid with optimal TR value was selected to manufacture. 
Dosimetric characteristics of the Grid were measured using 
ionization chamber in water phantom and Gafchoromic film 
dosimeter in Solid WaterTM phantom materials.  
 
Results: The results from the Monte Carlo studies showed 
that increasing the spacing between the Grid holes with a 
given hole diameter keep the TR value of the Grid block 
nearly unchanged (±4%). Moreover, a Grid block with a hole-
diameter of 1.0 cm and 1.25 cm may lead to about 19% 
higher clinical responses relative to the Grids with hole-
diameters smaller than 1.0 cm or larger than 1.25 cm. 
Dosimetric measurements of the optimal Grid were in good 
agreement (± 5%) using different dosimetry techniques. Table 
1 shows comparison between different dosimetric features of 
the manufactured Grid and the dosimtric features that were 
predicted by Monte Carlo simulation. 
Table 1 
 
 
 
Conclusion: Designed Grid block leads to have an optimal 
therapeutic ratio for spatially fractionated radiation therapy. 
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Purpose or Objective: Korea Radiation Oncology Group 
(KROG)-0806 study has been the phase Ⅲ randomized trial to 
investigate the efficacy of internal mammary node(IMN) 
irradiation in breast cancer patients. Previous dummy run 
study evaluated protocol compliance of participating 
institutions. The purpose of this study is to assess the 
protocol compliance based on individual cases review (ICR). 
 
Material and Methods: For ICR, patients were divided into 
eight subgroups based on IMN irradiation (non-irradiation (N) 
vs. Irradiation (R), tumor laterality (left-side (L) vs. right-side 
(R)) and type of surgery (breast-conserving surgery (B) vs. 
mastectomy (M)), respectively: NLB, NRB, NLM, NRM, RLB, 
RRB, RLM and RRM. We extracted 15% among patients 
enrolled in each subgroup using the SURVEYSELECT procedure 
with the simple random sample. Then, all participating 
institutions were requested to upload the following 
information: planning computed tomography (CT) images, 
structure sets, and radiation doses as well as the documents 
containing treatment techniques and all beams’ eye views 
with questionnaire. We performed the comparison of the 
dose distribution among 8 subgroups. Major and minor 
violations are determined according to IMN treatment and 
dose delivered to IMN. 
 
Results: The information of 102 patients was collected. 
Institutions used the different treatment techniques such as 
standard tangents (42.2%), partial wide tangent (23.5%), 
30/70 photon/electron mix (17.6%), IMN-electron only (4.9%), 
and reverse hockey stick (11.8%). The IMN average doses in 
subgroups were as follows: Arm1[NLB(14.9Gy±10.7Gy), 
NRB(18.5Gy±13.0Gy), NLM(27.7Gy±16.4Gy), 
NRM(27.5Gy±15.1Gy)] and Arm2[RLB(48.3Gy±4.5Gy), 
RRB(50.9Gy±4.1Gy), RLM(49.3Gy±4.1Gy), RRM 
(51.3Gy±3.2Gy)]. The dose differences between Arm1 and 
Arm2 groups were statistically significant. Dose variations in 
IMN were much greater in Arm1 than Arm2. In Arm1 group, 
